Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
268.46
-2.56 (-0.94%)
At close: Mar 28, 2025, 4:00 PM
266.00
-2.46 (-0.92%)
After-hours: Mar 28, 2025, 7:58 PM EDT

Company Description

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia.

It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders.

In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer’s disease; and ALN-HTT02 that is in phase I clinical trial for Huntington’s disease.

Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3.

It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals logo
Country United States
Founded 2002
IPO Date May 28, 2004
Industry Biotechnology
Sector Healthcare
Employees 2,100
CEO Yvonne Greenstreet

Contact Details

Address:
675 West Kendall Street, Henri A. Termeer Square
Cambridge, Massachusetts 02142
United States
Phone 617 551 8200
Website alnylam.com

Stock Details

Ticker Symbol ALNY
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001178670
CUSIP Number 02043Q107
ISIN Number US02043Q1076
Employer ID 77-0602661
SIC Code 2834

Key Executives

Name Position
Dr. Yvonne L. Greenstreet M.B.A., M.D. Chief Executive Officer and Director
Dr. Phillip A. Sharp Ph.D. Co-Founder, Member of the Scientific Advisory Board and Independent Director
Jeffrey V. Poulton M.B.A. Chief Financial Officer and Executive Vice President
Dr. Akshay K. Vaishnaw M.D., Ph.D. Chief Innovation Officer and Member of the Scientific Advisory Board
Dr. Pushkal P. Garg M.D. Chief Medical Officer
Tolga Tanguler M.B.A. Executive Vice President and Chief Commercial Officer
Timothy J. Maines Chief Technical Operations and Quality Officer
Dr. Kevin Joseph Fitzgerald Ph.D. Senior Vice President, Head of Research and Chief Scientific Officer
Piyush Sharma J.D. Chief Ethics and Compliance Officer
Robert W. Hesslein Esq., J.D. Chief Legal Officer and Corporate Secretary

Latest SEC Filings

Date Type Title
Mar 24, 2025 ARS Filing
Mar 24, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 24, 2025 DEF 14A Other definitive proxy statements
Mar 24, 2025 144 Filing
Mar 24, 2025 144 Filing
Mar 21, 2025 144 Filing
Mar 21, 2025 8-K Current Report
Mar 14, 2025 PRE 14A Other preliminary proxy statements
Mar 5, 2025 8-K Current Report
Mar 4, 2025 144 Filing